The Fidelity OTC Portfolio’s third-quarter 2026 review offers a snapshot of how a growth-oriented equity fund is positioning around artificial intelligence, semiconductors, and changing market risk. For industrial automation leaders and technology decision-makers, the portfolio’s themes are relevant as indicators of how public-market investors are assessing AI infrastructure demand and the companies supplying it. They are investment observations, however, rather than a guide to industrial technology purchasing decisions.
Fidelity OTC Portfolio performance in Q3 2026
For the three months ended September 30, 2026, the fund’s Retail Class shares returned 3.27%, compared with 2.61% for the NASDAQ Composite Index and 1.13% for the Morningstar Large Growth category. The fund also reported higher returns than those comparisons over the one-, three-, five-, and ten-year periods shown in its review. These are historical results, not a promise of future performance; investment value and returns can fluctuate.
The review describes a quarter in which U.S. growth stocks advanced modestly despite geopolitical concerns, higher oil prices, rising bond yields, and a Federal Reserve rate increase. Strong earnings, improved labor-market conditions, resilient consumer spending, and investment in AI infrastructure were identified as positive forces. Large-cap stocks outperformed small-cap stocks in that environment, while higher borrowing costs weighed on smaller companies.
AI infrastructure and semiconductor exposure
Artificial intelligence remained a central investment theme. The portfolio manager noted that investment in AI infrastructure had supported economic growth and some equity prices, while also emphasizing the need to assess whether investors are being adequately compensated for the risks. The review pointed to surging Treasury yields, persistent inflation pressure, and elevated oil prices as reasons the perceived level of risk had increased by quarter end.
Information technology represented 58.03% of portfolio assets at September 30, against 54.81% for the benchmark, an overweight of 3.22 percentage points. Semiconductor and semiconductor-equipment holdings accounted for much of that positioning. Taiwan Semiconductor Manufacturing and Nvidia were identified as two of the portfolio’s largest overweight positions. Nvidia was also one of its largest holdings by issuer, at 13.38% of net assets.
The fund’s commentary connected this exposure to demand for AI computing. Nvidia’s reported results for the three months ending July 26 included higher revenue, led by its data-center business, and earnings above consensus expectations. The review also cited management’s sales outlook as a factor in the share’s performance. These observations describe the quarter’s investment rationale; they do not establish how demand or company results will develop in the future.
Agentic AI and the role of CPUs
The review also discussed Intel in the context of agentic AI. Its investment case was based on the view that agentic tasks—which involve coordinating multiple discrete tasks—may rely on central processing units supported by graphics-processing-unit accelerators, rather than GPUs alone. The manager suggested this could create an opportunity for a company with a long history in CPUs. This is a portfolio view, not a technical conclusion that applies to every AI workload or system design.
Health care allocation and stock selection
Health care was another notable area of portfolio activity. Its allocation rose during the quarter, reaching 8.96% of the portfolio compared with 5.26% for the index. The review cited Illumina, Natera, and 10x Genomics among the companies that contributed to the decision to increase exposure, based on the manager’s assessment of their growth potential and valuations.
Stock selection in health care was a leading contributor to relative results. An overweight in Moderna contributed the most versus the benchmark, following a reported increase in its share price and positive late-stage trial results for an mRNA-based therapy for high-risk melanoma being developed with Merck. An overweight in Crinetics Pharmaceuticals also contributed after Vertex Pharmaceuticals announced an agreement to acquire the company; the deal was completed on September 1, according to the review.
Not all holdings helped performance. An overweight in Space Exploration Technologies detracted, while an underweight in Microsoft also hurt relative returns as Microsoft shares rose after results reflecting growth in Azure and paid AI subscribers. These examples illustrate how both owning less of a rising stock and holding a larger position in a falling one can affect performance relative to a benchmark.
Portfolio concentration and risk considerations
The fund held 125 securities, but its ten largest holdings represented 61.02% of net assets. Its ten largest issuers accounted for 64.68%. This concentration is important context when considering the results: a relatively small number of large positions can have a substantial influence on performance. The review also reported a three-year standard deviation of 18.41%, compared with 17.14% for the index, and a beta of 1.02 versus 1.00. These historical measures describe past variability and do not predict future outcomes.
Other risks identified in the fund materials include technology obsolescence, short product cycles, competition, and the potential volatility of smaller or less widely known companies. The fund may also experience additional volatility because it can invest a significant portion of assets in a small number of issuers. Its growth-oriented approach seeks companies with above-average earnings potential and sustainable business models that the manager believes the market has mispriced, using bottom-up fundamental analysis.
What the review means for automation decision-makers
For industrial automation organizations, the practical takeaway is not to treat a portfolio’s holdings as a forecast of technology adoption. Rather, the review shows that investors were closely watching AI infrastructure, semiconductor suppliers, and the possible mix of processing resources behind emerging AI workloads. Those themes can inform market awareness, but they do not replace application-specific evaluation of performance requirements, integration, lifecycle needs, or cost.
The Fidelity OTC Portfolio ended the quarter with significant technology exposure, a higher health care allocation, and explicit caution about elevated market risk. Its results also demonstrate the influence of stock selection and concentrated positions on relative performance. As with any equity fund, past returns and current positioning are not guarantees of future results, and the fund’s stated risks should be considered alongside its investment objectives and expenses.